Mazdutide: What Does Approval in China Mean for the UK?

Understanding mazdutide and overseas approval

Mazdutide has been approved for weight management in China. If you have seen the trial results and wondered whether you can get it here, this guide explains what they show and why The Care Pharmacy does not currently offer it.

Mazdutide evidence guide: a woman unpacking shopping at home, with The Care Pharmacy branding

What is mazdutide?

Mazdutide is a medicine that activates glucagon and GLP-1 receptors. These hormone pathways are involved in appetite and metabolism. It has been developed for weight management and type 2 diabetes, with much of the published programme conducted in China.

You may see the development code IBI362. It refers to mazdutide, rather than a separate medicine. It is also different from semaglutide, the ingredient in Wegovy, and tirzepatide, the ingredient in Mounjaro.

The manufacturer announced Chinese approval for chronic weight management in June 2025. That was approval by China’s National Medical Products Administration for a defined use in that country.

The Care Pharmacy does not offer mazdutide. News of an overseas approval should not be read as an announcement that it can be prescribed or ordered through our UK service.

What did the mazdutide GLORY-1 trial find?

The phase 3 GLORY-1 study enrolled 610 adults in China with overweight or obesity. It compared two mazdutide treatment groups with placebo over 48 weeks.

At week 48, average weight loss was 11.0% and 14.01% in the mazdutide groups. The placebo group had an average weight increase of 0.30%. These estimates accounted for people who stopped treatment or started another weight-loss therapy.

The study’s main assessment was at 32 weeks, so some reports quote that earlier result. If two articles use different numbers, check the time point and treatment group before assuming one is wrong.

A group average is not a personal prediction. The study tells us what happened in the population tested, with the study’s monitoring and support. It does not establish what every UK patient would experience.

It also does not rank mazdutide against all other weight-loss medicines. A placebo-controlled study and a direct comparison with an existing medicine answer different questions.

Why does the study population matter?

Medicines can work across populations, but evidence still needs to be examined carefully. GLORY-1 enrolled Chinese adults using its own BMI entry criteria. Those criteria should not be copied as eligibility rules for a UK prescription.

A prescriber needs evidence relevant to the person being treated, including their health conditions, other medicines and previous care. Differences in who joins a trial can affect the result, as can its duration and the way treatment is started.

There is also published phase 2 research from the United States. That study tested mazdutide in adults without type 2 diabetes, using a different design and treatment groups. It adds information, but it does not turn the Chinese approval into UK approval.

When reading a large percentage quoted online, check which trial produced it. A result from a different study or dose should not be attached to the GLORY-1 study simply because the compound has the same name.

What mazdutide side effects have been reported?

Digestive symptoms were the most frequently reported adverse events in GLORY-1 and were mostly mild to moderate. Some participants stopped treatment because of side effects. Those findings need to be considered alongside weight loss.

Terms such as “well tolerated” are summaries of a particular study. They do not mean a medicine is free from side effects or suitable for everyone. The most useful information includes how symptoms affected daily life and how often people could continue treatment.

A low number of people stopping treatment does not rule out uncommon harms. Neither does the absence of a particular problem in one trial. Longer follow-up and wider clinical use can reveal information that early studies cannot.

If you already take a weight-loss medicine, do not assume mazdutide would avoid a side effect you have experienced. That needs an individual discussion, and it is not a reason to buy an unfamiliar product online or combine treatments yourself.

Speak to your prescriber if symptoms are making treatment difficult. You can ask for a review without waiting for a future UK product launch.

Does approval in China mean UK approval is next?

Not necessarily. Each regulatory system has its own process. A company would need to pursue the relevant UK authorisation, and the MHRA would assess the evidence submitted for the proposed use.

An overseas decision can be important evidence of a medicine’s development, but it does not set a UK timetable. Announcements about research partnerships, commercial plans or manufacturing also do not establish a UK supply date.

There are several separate questions:

  • Has the medicine been authorised for the intended use in the UK?
  • Is a regulated UK service actually able to supply it?
  • Would it be suitable for the individual patient?
  • Is it funded through the NHS, or would care be private?

A yes to one does not settle all the others. In particular, a medicine becoming available privately would not automatically mean NHS access for everyone who wants it.

Can you buy mazdutide from The Care Pharmacy?

No. We do not supply mazdutide, and there is no UK prescription price or supply date to announce through our service.

Be careful with overseas websites or social media accounts offering a product under this name. An order page does not establish that the product is the medicine used in the trials, that it has been stored correctly or that it is suitable for you.

A Chinese brand name, a photograph of packaging or a claimed purity result cannot answer all those questions. Trying to import a treatment yourself also leaves practical problems around prescribing, monitoring and help if you become unwell.

We cannot provide a dosing, switching or importing plan for mazdutide. If your aim is to start weight-management treatment, an assessment of options already offered through a regulated service is a more appropriate next step.

Considering private weight-loss treatment in the UK

You can explore current options without waiting for a particular overseas medicine. The NHS guide to overweight and obesity explains the range of care, from help with eating and activity to medicines and specialist treatment.

A private consultation should consider your health and current medicines, rather than begin with a promise to provide the product you ask for. Tell the prescriber about previous weight-loss treatment, side effects and anything bought online.

Compare the service as well as the pack price. Check what follow-up is included, who you can contact about symptoms and how repeat prescriptions are reviewed. An introductory price does not tell you the likely cost of ongoing care.

Before your first prescription, the clinician should explain how your dose would be increased and when they would check how you are getting on. You should also have a chance to discuss what success would look like for you. Better health, manageable side effects and a realistic follow-up plan matter alongside changes on the scales.

Common questions about mazdutide

Is it a different name for Mounjaro?

No. Mazdutide and tirzepatide are different compounds. Their hormone targets are not identical, and evidence about one should not be presented as evidence about the other.

Does the 14% result apply to everyone?

No. It is an average from a treatment group at a particular time point in GLORY-1. Individual results varied, and the trial cannot predict your outcome.

Can I use Chinese trial entry criteria to check my eligibility?

No. A research study’s entry rules are not UK prescribing instructions. Eligibility for an available treatment depends on its approved use and an individual clinical assessment.

Can your weight-loss consultation provide mazdutide?

No. The Care Pharmacy does not offer it. Our consultation assesses whether currently offered prescription treatment is suitable for you.

Find out whether weight-loss treatment is suitable for you

If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.

Start consultation

This guide gives general information. Ask a qualified healthcare professional about your own treatment.

Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.

Clinical reviewer

Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.

Medically reviewed by

Mohammed Lakhi

Superintendent Pharmacist

Muhammad Lahki
Mohammed Ismail Lakhi

Ecnoglutide: What Can UK Readers Learn From the Trials?

Ecnoglutide is another name appearing in weight-management research. This guide explains its own trial evidence and the limits of overseas approval.

Read More

Survodutide: What Do Its Weight-Loss Trials Tell Us?

Survodutide is a separate treatment under development. Read what its obesity research has measured and why trial results need context.

Read More

MariTide: What Do We Know About Amgen’s Treatment?

MariTide and maridebart cafraglutide refer to the same investigational treatment. Here is what its research programme can tell UK readers.

Read More

Petrelintide: What Is This Amylin Treatment?

Petrelintide is an investigational amylin treatment. Read what the studies have measured and why a trial result is different from a treatment recommendation.

Read More

Eloralintide: What Do the Weight-Loss Trials Show?

Eloralintide is being studied as a weight-management treatment. This guide explains the trial findings and the questions they have yet to answer.

Read More

Orforglipron: Eli Lilly’s New Oral GLP-1 Weight Loss Treatment

A new clinical analysis suggests that orforglipron, Eli Lilly’s first GLP-1 weight-loss pill, may become a strong alternative to weekly injections like Wegovy and Mounjaro. The findings come from the latest GLP-1 study 2025, where researchers reported meaningful reductions in body weight, improved blood sugar control, and benefits for adults living with type 2 diabetes […]

Read More
icon
UK-Prescribing Pharmacists
icon
No GP Appointments Needed
icon
Fast & Discreet Delivery